在复发的多发性骨髓瘤中克服达拉图穆马布的严重反应与脱敏
Trang L Nguyen1, Truc Phan2, Mai T Vu3
1Pharmacy Department, Vinmec Times City General Hospital, Hanoi, Vietnam.
概括
多发性骨髓瘤患者的达拉图穆马布输液反应可能是严重的. 这种案例研究表明,成功的脱敏使患者能够继续治疗,并获得非常好的部分反应.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 达拉图马布是一种针对CD38的单克隆抗体,用于复发性多发性髓瘤.
- 输液相关反应的高率 (高达38%) 复杂化了达拉图穆马布治疗,特别是初始剂量.
- 严重的输液反应需要终止治疗,这对患者管理构成了挑战.
研究的目的:
- 描述一个多发性骨髓瘤患者成功脱敏的案例,该患者经历了严重的Daratumumab输液反应.
- 为了评估达拉图穆马布 (Daratumumab) 管理的脱敏方案的有效性和安全性.
主要方法:
- 一名60岁的男性多发性骨髓瘤患者经历了初始达拉图穆马布剂量3级输液反应.
- 在反应管理之后,实施了一项脱敏方案,包括逐步重新引入达拉图姆巴.
- 皮肤测试 (刺入和皮肤内测) 达拉图穆马布在脱敏化之前进行,结果是负面的.
主要成果:
- 达拉图穆马布无敏化方案是成功的,在给药期间没有观察到任何不良事件.
- 患者在成功脱敏后可以容忍随后的Daratumumab循环.
- 经过三次循环,患者实现了非常良好的部分反应 (VGPR),没有疾病进展.
结论:
- 脱敏是一种可行的策略,用于管理多发性骨髓瘤中对达拉图穆马布的严重输液反应.
- 成功消毒使得Daratumumab治疗的继续成为可能,改善了患者的治疗结果.
- 多学科团队的方法对于安全有效的达拉图穆马布脱敏至关重要.
更多相关视频
11:55Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
Published on: March 14, 2011
14.7K
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
3.5K
相关概念视频
Desensitization and Tachyphylaxis
2.2K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
2.2K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Tumor Immunotherapy
665
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
665
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
